文献速递关节外科创伤骨科骨肿瘤

阿司匹林在全髋关节置换术后血液系统恶性肿瘤患者中优于抗凝药的静脉血栓栓塞预防

Aspirin Is Associated With Improved Venous Thromboembolism Prophylaxis Compared With Anticoagulants After Total Hip Arthroplasty in Patients Who Have Prior Hematologic Malignancy.
PubMed 文献 · J Arthroplasty · 2026-06-09

该回顾性队列研究利用全国行政数据库,纳入2010至2023年间接受全髋关节置换术且有血液系统恶性肿瘤病史的患者,经倾向评分匹配后比较阿司匹林与非阿司匹林抗凝药的静脉血栓栓塞预防效果。结果显示阿司匹林组90天深静脉血栓发生率更低(0.3%比1.1%),且急诊就诊、再入院、输血和肺炎风险均降低,支持阿司匹林作为安全选择。

要点

  • 阿司匹林组90天深静脉血栓发生率0.3%,低于非阿司匹林抗凝组的1.1%。
  • 阿司匹林组急诊就诊、再入院、输血和肺炎风险均显著低于非阿司匹林抗凝组。
  • 华法林和低分子肝素与阿司匹林相比静脉血栓栓塞风险更高,直接口服抗凝药组无静脉血栓栓塞事件。

核心结论

  • 全髋关节置换术后有血液系统恶性肿瘤病史的患者,阿司匹林预防静脉血栓栓塞优于抗凝药且术后并发症更少,支持其作为安全选择。

研究设计与样本

  • 回顾性队列研究,利用全国行政数据库识别2010至2023年间诊断为血液系统恶性肿瘤并接受全髋关节置换术的患者。
  • 经倾向评分匹配后,阿司匹林组1043例与非阿司匹林抗凝组1484例在人口学和合并症上匹配。
  • 主要结局为90天静脉血栓栓塞,次要结局包括术后并发症、再入院和死亡,并作亚组分析。

主要发现

  • 90天时阿司匹林组深静脉血栓发生率为0.3%,非阿司匹林抗凝组为1.1%(OR 0.25 [0.07至0.85];P=0.03)。
  • 两组肺栓塞或死亡率无差异。
  • 阿司匹林组急诊就诊(OR 0.62 [0.48至0.80];P<0.001)、再入院(OR 0.57 [0.41至0.80];P=0.001)、输血(OR 0.44 [0.25至0.76];P=0.004)和肺炎(OR 0.38 [0.19至0.76];P=0.008)更少。
  • 华法林和低分子肝素与阿司匹林相比静脉血栓栓塞风险更高(OR分别为9.12和10.06;P≤0.002),直接口服抗凝药组无静脉血栓栓塞事件。
  • Cox比例风险模型显示阿司匹林组90天深静脉血栓风险降低(HR 0.21 [0.06至0.71])。

临床怎么用

  • 对于有近期或远期血液系统恶性肿瘤病史行全髋关节置换术的患者,可考虑使用阿司匹林作为静脉血栓栓塞预防的安全选择。

局限性

  • 证据等级为III级(回顾性队列研究)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who have prior hematologic malignancies undergoing total hip arthroplasty (THA) have elevated venous thromboembolism (VTE) risk. Although guidelines favor low-molecular weight heparin or direct oral anticoagulants in high-risk patients, these agents may increase bleeding and wound complications. Evidence supporting aspirin in this population remains limited. METHODS: A national administrative database identified patients diagnosed with a hematologic malignancy and underwent THA between 2010 and 2023. Patients were stratified by postoperative VTE prophylaxis. After propensity score matching, 1,043 patients who received aspirin were matched to 1,484 patients who received nonaspirin anticoagulation on demographics and comorbidities. The primary outcome was 90-day VTE. The secondary outcomes included postoperative complications, readmissions, and mortalities. Subgroup analyses evaluated malignancy-to-THA timing and anticoagulant classes. RESULTS: At 90 days, aspirin was associated with lower deep vein thrombosis rates compared with nonaspirin prophylaxis (0.3 versus 1.1%; odds ratio [OR] 0.25 [0.07 to 0.85]; P = 0.03). There were no differences in pulmonary embolism or mortality. Aspirin was associated with fewer emergency department visits (OR 0.62 [0.48 to 0.80]; P < 0.001), readmissions (OR 0.57 [0.41 to 0.80]; P = 0.001), transfusions (OR 0.44 [0.25 to 0.76]; P = 0.004), and pneumonia (OR 0.38 [0.19 to 0.76]; P = 0.008). Warfarin and low-molecular weight heparin were associated with higher VTE odds compared with aspirin (OR 9.12 and 10.06, respectively; P ≤ 0.002), while no VTE events occurred in the direct oral anticoagulant group. On Cox proportional hazards modeling, patients who received aspirin demonstrated a reduced rate of 90-day deep vein thrombosis compared with those who received nonaspirin anticoagulation (hazard ratio [HR] 0.21 [0.06 to 0.71]). CONCLUSIONS: Aspirin prophylaxis after THA in patients who have prior hematologic malignancy was associated with improved VTE prevention compared with anticoagulants and fewer postoperative complications, supporting its use as a safe option in patients who have recent or remote hematological malignancies. LEVEL OF EVIDENCE: III (Retrospective Cohort Study).

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Paul BR, Verhey JT, Tarabichi S, et al. Aspirin Is Associated With Improved Venous Thromboembolism Prophylaxis Compared With Anticoagulants After Total Hip Arthroplasty in Patients Who Have Prior Hematologic Malignancy. J Arthroplasty. 2026. PMID: 42264104. doi:10.1016/j.arth.2026.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。